Jpmorgan Chase & CO Icosavax, Inc. Transaction History

Jpmorgan Chase & CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$5.95 - $15.79 $64,051 - $169,979	10,765 Added 57.17%	29,594 $466,000
Q3 2023 Nov 14, 2023	SELL	$7.22 - $10.05 $19,234 - $26,773	-2,664 Reduced 12.39%	18,829 $145,000
Q2 2023 Aug 11, 2023	BUY	$4.89 - $10.57 $21,163 - $45,746	4,328 Added 25.21%	21,493 $213,000
Q1 2023 May 18, 2023	BUY	$5.62 - $11.51 $95,697 - $195,992	17,028 Added 12429.2%	17,165 $99,000
Q1 2023 May 11, 2023	SELL	$5.62 - $11.51 $84,536 - $173,133	-15,042 Reduced 99.1%	137 $0
Q4 2022 Feb 13, 2023	SELL	$2.32 - $10.97 $1,252 - $5,923	-540 Reduced 3.44%	15,179 $121,000
Q3 2022 Nov 14, 2022	SELL	$3.09 - $9.21 $144,500 - $430,696	-46,764 Reduced 74.84%	15,719 $50,000
Q2 2022 Aug 11, 2022	BUY	$5.7 - $10.33 $244,729 - $443,518	42,935 Added 219.64%	62,483 $358,000
Q1 2022 May 11, 2022	BUY	$4.41 - $22.5 $34,764 - $177,367	7,883 Added 67.58%	19,548 $138,000
Q4 2021 Feb 10, 2022	BUY	$21.07 - $34.98 $141,948 - $235,660	6,737 Added 136.71%	11,665 $268,000
Q3 2021 Nov 12, 2021	BUY	$24.85 - $40.25 $122,460 - $198,352	4,928 New	4,928 $146,000

1.37M

Ticker ICVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,885,200
Description
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical tri...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.